Nuclear medicine innovations help (drive) healthcare (benefits)

doi:10.1007/s00259-014-2957-6

Paper

Nuclear medicine innovations help (drive) healthcare (benefits)

Published Nov 22, 2014 · M. Hacker, T. Beyer, R. Baum

European Journal of Nuclear Medicine and Molecular Imaging

Q1 SJR score

9

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Nuclear medicine is an integral part of modern healthcare. It uses biomolecules tagged with radioactive isotopes that can recognize different molecular targets in the body or seek out hallmarks of malignant and benign conditions. The distribution of trace amounts of a radioactively labelled molecule, known as a radiotracer, can be mapped and followed noninvasively anywhere in the human body using a dedicated system, such as a single photon emission computed tomography (SPECT) system or a positron emission tomography (PET) system. This trace approach provides longitudinal sets of volumetric and quantitative images that can be used to diagnose a wide range of diseases and/or assess response to disease-specific treatments. Replacing these diagnostic radionuclides with alternative nuclides that emit a different type of radiation converts imaging tracers into drugs that deliver potent and targeted molecular treatment. Recent advances have extended the range of molecular radiotherapies, which are now applied across a broad spectrum of diseases from arthritis and benign thyroid diseases to many types of cancer. As such, nuclear medicine is in a key position to bring personalized or image-guided therapy into routine clinical practice. This key position is supported by the rapidly expanding fields of radiochemistry and radiopharmacy with novel kitlike or cassette-type labelling techniques which allow shorter turn-aroundtimesfromtheidentificationoftherapeutictargets to the design and evaluation of associated radiotracers, resulting in lower development costs. Over the past 5 years, significant technological breakthroughs in imaging hardware and image processing algorithms have also been introduced, enabling specific radiotracer imaging for improved characterization of targeted cellular and functional processes in clinical

Study Snapshot

Nuclear medicine innovations enable personalized or image-guided therapy, enabling targeted molecular treatment for various diseases and reducing healthcare costs.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Nuclear medicine innovations help (drive) healthcare (benefits)

Sign up to use Study Snapshot

References

Citations

A scoping review of person-centred care strategies used in diagnostic Nuclear Medicine.

Person-centered care strategies in nuclear medicine can improve patient experience, comfort, knowledge, and reduce anxiety, leading to enhanced clinical outcomes.

Targeting Estrogen Signaling in the Radiation-induced Neurodegeneration: A Possible Role of Phytoestrogens

Phytoestrogens may offer neuroprotection in radiation-induced brain degeneration, potentially improving patients' quality of life and cognitive function.

Topical Analysis of Nuclear Experts' Perceptions of Publics, Nuclear Energy, and Sustainable Futures

Nuclear experts perceive risk, safety, government, public education, engagement, and cost as key factors in shaping their communication practices and public engagement with nuclear energy.

Biomedical Applications of Targeted Drug Delivery, Nanotheranostic and Nuclear Medicine

Nanocarriers play a crucial role in disease diagnosis, therapy, imaging, and monitoring by delivering drugs to target tissues/cells.

Development of PSMA-1007 - Related Series of 18F-Labeled Glu-ureido type PSMA inhibitors.

PSMA-1007, a radiotracer based on the glu-ureido type PSMA inhibitor, shows the best interaction with the prostate specific-membrane antigen (PSMA) and is currently in advanced clinical trials for prostate cancer diagnosis.